Business Overview
Our Two Core Businesses
Development of digital therapeutics (DTx)
Our business consists of two pillars. The first is the development of smartphone-based DTx. We are currently developing DTx as approved medical devices for diseases such as insomnia, breast cancer, and kidney disease. Our engineering team and clinical development team are well versed in relevant medical fields and are working closely together to develop DTx.
Promotion of efficiency of clinical trials
The second is the provision of the SUSMED system to promote efficient drug development. Clinical trials are crucial for drug development but involve massive costs, which is one factor driving the sharp increase in drug prices. Using our proprietary blockchain technology enables to reduce cost and labor involved in clinical trials by securing the integrity of the clinical trial data.
Click here for details
To Achieve Sustainable Medicine
Reducing the workload of frontline medical personnel and lowering the cost of drug development are the twin pillars on which our company is built. We believe that they are powerful means of achieving our goal of sustainable medicine, the concept after which our company—SUSMED—is named. There is a serious lack of qualified personnel on the frontlines of clinical practice, so we want to reduce the workload of medical personnel by providing DTx as novel treatments.
In terms of clinical trials, the proprietary blockchain technology that we have developed for our SUSMED system makes it possible to dramatically slash costs by reducing the work involved in verifying trial data with records at medical institutions, a time-consuming task that has traditionally been carried out manually.
We aim to solve the problems facing medical care in Japan by achieving the efficient allocation of medical resources and boosting drug development efficiency, and, in so doing, show how sustainable medical care can be made a reality.
In terms of clinical trials, the proprietary blockchain technology that we have developed for our SUSMED system makes it possible to dramatically slash costs by reducing the work involved in verifying trial data with records at medical institutions, a time-consuming task that has traditionally been carried out manually.
We aim to solve the problems facing medical care in Japan by achieving the efficient allocation of medical resources and boosting drug development efficiency, and, in so doing, show how sustainable medical care can be made a reality.
Next Contents